



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2383496 A1 2001/01/18

(21) 2 383 496

B5

(12) DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION

(13) A1

(86) Date de dépôt PCT/PCT Filing Date: 2000/07/10
(87) Date publication PCT/PCT Publication Date: 2001/01/18
(85) Entrée phase nationale/National Entry: 2002/01/03
(86) N° demande PCT/PCT Application No.: NZ 2000/000121
(87) N° publication PCT/PCT Publication No.: 2001/004140
(30) Priorités/Priorities: 1999/07/12 (09/351,348) US;
1999/11/29 (09/450,072) US

(51) Cl.Int. 7/Int.Cl. 7 C07K 7/06, A61K 38/16, A61K 38/10,
A61K 38/08, C07K 7/08, C07H 21/00

(71) Demandeur/Applicant:
GENESIS RESEARCH & DEVELOPMENT
CORPORATION LIMITED, NZ

(72) Inventeur/Inventor:
DELCAYRE, ALAIN, US

(74) Agent: SMART & BIGGAR

(54) Titre : COMPOSES POUR LE TRAITEMENT DE MALADIES INFECTIEUSES OU DE TROUBLES DU SYSTEME
IMMUNITAIRE, ET METHODES D'UTILISATION DE CES COMPOSES

(54) Title: COMPOUNDS FOR TREATMENT OF INFECTIOUS AND IMMUNE SYSTEM DISORDERS AND METHODS
FOR THEIR USE

(57) Abrégé/Abstract:

The present invention provides polypeptides comprising an immunogenic epitope of a *M. vaccae* protein, polynucleotides encoding such polypeptides, and fusion proteins comprising at least one such polypeptide, together with DNA constructs comprising at least one inventive polynucleotide. Compositions comprising such polypeptides, polynucleotides, fusion proteins and/or DNA constructs may be employed in the treatment of infectious diseases and immune disorders.